WALTHAM, Mass. — Revvity, Inc. is unveiling a suite of new research solutions at the 2025 American Association for Cancer Research (AACR) Annual Meeting in Chicago, aimed at accelerating discoveries across cancer science. Among the highlights is the debut of the VivoJect™ Image-Guided Injection System, which integrates with the company’s Vega™ automated preclinical ultrasound system to enable real-time imaging and precise injections for high-throughput in vivo studies.
Designed to streamline workflows for applications such as tumor model development, targeted drug delivery, gene therapy, stem cell research, and cardiac studies, the VivoJect system marks a significant advancement in preclinical imaging technology. When paired with the Vega system, it offers researchers a more efficient and nimble method for conducting in vivo experiments compared to conventional techniques.
Revvity’s broader cancer research portfolio is also on display at booth #1200, featuring innovations such as the PhenoVue™ DNA Damage Response Staining Kit, the Harmony™ 5.3 and Phenologic.AI™ high-content image analysis software, and a diverse range of oncology reference standards from the Mimix™ portfolio. The company is further showcasing reagent technologies from BioLegend, including TotalSeq™ PhenoCyte, TotalSeq-A and -C Universal Cocktails, as well as high-sensitivity immunoassay kits.
“We’re combining cutting-edge science with innovative technology to support cancer researchers from early discovery through translational studies,” said Kevin Quick, vice president of platforms, life sciences at Revvity. “Our comprehensive solutions are designed to empower scientists at every stage of research, whether they are decoding cancer at the molecular level or developing new therapeutics.”
In addition to showcasing its imaging and analysis platforms, Revvity is presenting solutions across several key research areas at AACR. These include cell analysis in 3D environments using AI-driven tools, immunoassay technologies for biomarker detection, in vivo imaging platforms for tracking disease progression, and genomic solutions such as the Pin-point™ base editing platform and OMNI™ sample homogenizers.
The company is also contributing to scientific discourse at AACR through more than 10 posters authored or co-authored by Revvity employees. One of these posters, developed in collaboration with Charles River Laboratories, highlights the use of Revvity’s Vega automated preclinical ultrasound system in a longitudinal study tracking the progression of graft-versus-host disease.
With these latest innovations, Revvity continues to expand its presence in cancer research, offering tools and technologies that aim to accelerate the development of new diagnostics and therapeutics across the oncology landscape.
